Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26864272 | 0.93 | HRH3 (0.36) | HRH3KCNH2MAOB | |
| SCHEMBL27718537 | 0.80 | — | — | |
| SCHEMBL27718536 | 0.80 | SIGMAR1 (0.35) | MAOB | |
| SCHEMBL4438468 | 0.79 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL6465675 | 0.77 | DRD2 (0.35) | KCNH2MAOB | |
| SCHEMBL21613894 | 0.77 | MAOA (0.32) | MAOB | |
| SCHEMBL27012408 | 0.76 | HRH3 (0.37) | HRH3KCNH2 | |
| SCHEMBL26889920 | 0.76 | HRH3 (0.31) | HRH3 | |
| SCHEMBL6204535 | 0.76 | NCF1 (0.50) | HRH3MAOB | |
| SCHEMBL25122685 | 0.75 | HRH3 (0.50) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | claimed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | HRH3 4540/4885KCNH2 3956/4885MAOB 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.